首页> 美国卫生研究院文献>Molecules >Theoretical Studies Aimed at Finding FLT3 Inhibitors and a Promising Compound and Molecular Pattern with Dual Aurora B/FLT3 Activity
【2h】

Theoretical Studies Aimed at Finding FLT3 Inhibitors and a Promising Compound and Molecular Pattern with Dual Aurora B/FLT3 Activity

机译:旨在寻找具有双重极光B / FLT3活性的FLT3抑制剂和有前途的化合物和分子模式的理论研究

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

FLT3 and dual Aurora B/FLT3 inhibitors have shown relevance in the search for promising new anticancer compounds, mainly for acute myeloid leukemia (AML). This study was designed to investigate the interactions between human FLT3 in the kinase domain with several indolin−2-one derivatives, structurally similar to Sunitinib. Molegro Virtual Docker (MVD) software was utilized in docking analyses. The predicted model of the training group, considering nineteen amino acid residues, performed in Chemoface, achieved an R of 0.82, suggesting that the binding conformations of the ligands with FLT3 are reasonable, and the data can be used to predict the interaction energy of other FLT3 inhibitors with similar molecular patterns. The MolDock Score for energy for compound 1 showed more stable interaction energy (–233.25 kcal mol ) than the other inhibitors studied, while Sunitinib presented as one of the least stable (–160.94 kcal mol ). Compounds IAF70, IAF72, IAF75, IAF80, IAF84, and IAF88 can be highlighted as promising derivatives for synthesis and biological evaluation against FLT3. Furthermore, IAF79 can be considered to be a promising dual Aurora B/FLT3 inhibitor, and its molecular pattern can be exploited synthetically to search for new indolin−2-one derivatives that may become drugs used in the treatment of cancers, including AML.
机译:FLT3和双重Aurora B / FLT3抑制剂在寻找有希望的新抗癌化合物(主要用于急性髓细胞白血病(AML))方面具有相关性。这项研究旨在研究激酶结构域中人类FLT3与几种与Sunitinib结构相似的吲哚-2衍生物之间的相互作用。 Molegro虚拟Docker(MVD)软件用于对接分析。考虑到19个氨基酸残基,在Chemoface中进行的训练组预测模型的R值为0.82,这表明配体与FLT3的结合构象是合理的,该数据可用于预测其他分子的相互作用能。具有相似分子模式的FLT3抑制剂。化合物1的MolDock能量分数显示出比其他研究的抑制剂更稳定的相互作用能(–233.25 kcal mol),而舒尼替尼则表现为最不稳定的相互作用能量(–160.94 kcal mol)之一。可以将化合物IAF70,IAF72,IAF75,IAF80,IAF84和IAF88突出显示为有望用于合成和针对FLT3进行生物学评估的衍生物。此外,IAF79被认为是一种有前途的双重Aurora B / FLT3抑制剂,其分子模式可以综合利用以寻找新的吲哚-2-酮衍生物,这些衍生物可能成为治疗包括AML在内的癌症的药物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号